AssetMark Inc
ORIC icon

AssetMark Inc’s Oric Pharmaceuticals ORIC Stock Holding History

AssetMark Inc’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.9K Sell
2,945
-55
-2% -$499 ﹤0.01% 2014
2026
Q1 		$38K Hold
3,000
– – ﹤0.01% 1841
2025
Q4 		$24.5K Sell
3,000
-89
-3% -$1.02K ﹤0.01% 1938
2025
Q3 		$37.1K Buy
+3,089
New +$32.5K ﹤0.01% 1734

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AssetMark Inc's ORIC Position: Q2 2026 in Review

AssetMark Inc reduced its Oric Pharmaceuticals (ORIC) stake by 1.8% in Q2 2026, selling an estimated $499 and leaving 2,945 shares worth $31.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2014.

AssetMark Inc first reported a position in ORIC in Q3 2025 and has held it in 4 quarters since. The position peaked at $38K in Q1 2026. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • AssetMark Inc held 2,945 shares of Oric Pharmaceuticals worth $31.9K as of Q2 2026.
  • AssetMark Inc sold 55 Oric Pharmaceuticals shares in Q2 2026, an estimated $499.
  • Oric Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #2014 holding.
  • AssetMark Inc first reported a position in Oric Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • AssetMark Inc's Oric Pharmaceuticals position peaked at $38K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.